Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
Background. The development of unique immune-related adverse events (irAEs) is a known hallmark of immunotherapy. Generally, such complications occur during the first 3–6 months of immunotherapy, however, the experience with immune checkpoint inhibitors (ICIs) shows that irAEs can also occur after c...
Saved in:
Main Authors: | E. A. Degtiareva, S. A. Protsenko, E. N. Imyanitov, G. M. Teletaeva, D. Kh. Latipova, A. I. Semenova, A. V. Novik |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2022-11-01
|
Series: | Сибирский онкологический журнал |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/2322 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune checkpoint inhibitors for the treatment of solid tumors in HIV-infected patients: is it worth the risk?
by: E. A. Degtiareva, et al.
Published: (2023-02-01) -
Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach
by: Özkan ALAN, et al.
Published: (2025-04-01) -
Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01) -
Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report
by: Nidhi Kuchimanchi, et al.
Published: (2025-07-01) -
Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)